Iovance Biotherapeutics Inc (IOVA) — Cash Flow-to-Debt Ratio
Iovance Biotherapeutics Inc (IOVA) has a Cash Flow-to-Debt Ratio of -0.39x as of September 2025, meaning its operating cash flow of $-78.70 Million could theoretically repay 0% of its total liabilities ($202.66 Million) in one year. See how financially flexible is Iovance Biotherapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Iovance Biotherapeutics Inc Cash Flow-to-Debt Ratio (2008–2024)
Historical debt coverage capacity for Iovance Biotherapeutics Inc across 17 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Iovance Biotherapeutics Inc.
Annual Cash Flow-to-Debt Ratio for Iovance Biotherapeutics Inc (2008–2024)
Year-by-year debt coverage analysis for Iovance Biotherapeutics Inc. Check how high is Iovance Biotherapeutics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.76x | $-352.98 Million | $200.02 Million | ▲ +4.5% |
| 2023 | -1.85x | $-361.82 Million | $195.74 Million | ▼ -3.8% |
| 2022 | -1.78x | $-292.76 Million | $164.34 Million | ▼ -21.7% |
| 2021 | -1.46x | $-227.94 Million | $155.67 Million | ▲ +20.1% |
| 2020 | -1.83x | $-205.13 Million | $111.96 Million | ▲ +47.3% |
| 2019 | -3.48x | $-158.89 Million | $45.68 Million | ▲ +49.8% |
| 2018 | -6.92x | $-101.25 Million | $14.63 Million | ▲ +13.0% |
| 2017 | -7.96x | $-78.71 Million | $9.89 Million | ▼ -21.0% |
| 2016 | -6.58x | $-32.67 Million | $4.97 Million | ▲ +41.7% |
| 2015 | -11.28x | $-18.38 Million | $1.63 Million | ▼ -117.1% |
| 2014 | -5.20x | $-8.63 Million | $1.66 Million | ▼ -222.0% |
| 2013 | -1.61x | $-3.66 Million | $2.27 Million | ▼ -716.9% |
| 2012 | -0.20x | $-2.24 Million | $11.35 Million | ▲ +57.4% |
| 2011 | -0.46x | $-6.19 Million | $13.35 Million | ▲ +38.5% |
| 2010 | -0.75x | $-620.80K | $822.87K | ▼ -20.7% |
| 2009 | -0.62x | $-14.45K | $23.12K | ▲ +96.4% |
| 2008 | -17.22x | $-57.30K | $3.33K | — |